Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company...
Cancer
Establishment Labs to Announce Fourth Quarter 2023 Financial Results on February 28
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
Establishment Labs to Announce Fourth Quarter 2023 Financial Results on February 28
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
KNOXVILLE, TN, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that...
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
BOSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer CenterTrial is Supported by...
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose...
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of...
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing...
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
VANCOUVER, BC / ACCESSWIRE / February 14, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharma...
Innsena Announces Impact Partnership with CancerX
Innsena’s $100,000 commitment will be used to accelerate the equitable deployment of innovations for all Americans, including our nation’s most...
Masimo Announces the First FDA-cleared “Over-the-Counter” Fingertip Pulse Oximeter
Masimo MightySat® Medical Provides Clinically Proven Masimo SET® Pulse Oximetry to Consumers for Medical Use Without a PrescriptionIRVINE, Calif.--(BUSINESS WIRE)--Masimo...
Masimo Announces the First FDA-cleared “Over-the-Counter” Fingertip Pulse Oximeter
Masimo MightySat® Medical Provides Clinically Proven Masimo SET® Pulse Oximetry to Consumers for Medical Use Without a PrescriptionIRVINE, Calif.--(BUSINESS WIRE)--Masimo...
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering...
The International Myeloma Foundation Launches the Iceland Cycling Expedition: A Fundraiser to Advance the Goals of the iStopMM Project and the IMF’s Robust Array of Research Initiatives
STUDIO CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is excited to announce the launch...
Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia
Tonmya™ is a potential new first-line therapy, non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from...
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company...
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy
Alleviates chemotherapy-induced neuropathyCounteracts tumor promoting signals induced by Antibody Drug Conjugate (ADC) payloadsLUND, SWEDEN / ACCESSWIRE / February 12, 2024...